NBY
Price
$0.52
Change
-$0.04 (-7.14%)
Updated
Apr 4, 04:56 PM (EDT)
Capitalization
3.27M
NCNA
Price
$0.79
Change
-$0.06 (-7.06%)
Updated
Apr 4, 04:55 PM (EDT)
Capitalization
5.18M
Ad is loading...

NBY vs NCNA

Header iconNBY vs NCNA Comparison
Open Charts NBY vs NCNABanner chart's image
NovaBay Pharmaceuticals
Price$0.52
Change-$0.04 (-7.14%)
Volume$700
Capitalization3.27M
NuCana
Price$0.79
Change-$0.06 (-7.06%)
Volume$199
Capitalization5.18M
NBY vs NCNA Comparison Chart
Loading...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NBY vs. NCNA commentary
Apr 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBY is a Hold and NCNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 06, 2025
Stock price -- (NBY: $0.56 vs. NCNA: $0.85)
Brand notoriety: NBY and NCNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NBY: 64% vs. NCNA: 73%
Market capitalization -- NBY: $3.27M vs. NCNA: $5.18M
NBY [@Biotechnology] is valued at $3.27M. NCNA’s [@Biotechnology] market capitalization is $5.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBY’s FA Score shows that 0 FA rating(s) are green whileNCNA’s FA Score has 1 green FA rating(s).

  • NBY’s FA Score: 0 green, 5 red.
  • NCNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both NBY and NCNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBY’s TA Score shows that 3 TA indicator(s) are bullish while NCNA’s TA Score has 3 bullish TA indicator(s).

  • NBY’s TA Score: 3 bullish, 5 bearish.
  • NCNA’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, NBY is a better buy in the short-term than NCNA.

Price Growth

NBY (@Biotechnology) experienced а -7.67% price change this week, while NCNA (@Biotechnology) price change was -20.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.75%. For the same industry, the average monthly price growth was -16.58%, and the average quarterly price growth was -18.37%.

Reported Earning Dates

NBY is expected to report earnings on May 11, 2023.

NCNA is expected to report earnings on Aug 14, 2024.

Industries' Descriptions

@Biotechnology (-10.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NCNA($5.18M) has a higher market cap than NBY($3.27M). NBY YTD gains are higher at: -6.439 vs. NCNA (-28.571). NBY has higher annual earnings (EBITDA): -6.52M vs. NCNA (-22.48M). NCNA has more cash in the bank: 6.75M vs. NBY (776K). NCNA has less debt than NBY: NCNA (190K) vs NBY (1.26M). NBY has higher revenues than NCNA: NBY (13.8M) vs NCNA (0).
NBYNCNANBY / NCNA
Capitalization3.27M5.18M63%
EBITDA-6.52M-22.48M29%
Gain YTD-6.439-28.57123%
P/E RatioN/AN/A-
Revenue13.8M0-
Total Cash776K6.75M11%
Total Debt1.26M190K664%
FUNDAMENTALS RATINGS
NBY vs NCNA: Fundamental Ratings
NBY
NCNA
OUTLOOK RATING
1..100
6126
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
8191
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NCNA's Valuation (18) in the Biotechnology industry is in the same range as NBY (45). This means that NCNA’s stock grew similarly to NBY’s over the last 12 months.

NCNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NBY (100). This means that NCNA’s stock grew similarly to NBY’s over the last 12 months.

NCNA's SMR Rating (99) in the Biotechnology industry is in the same range as NBY (100). This means that NCNA’s stock grew similarly to NBY’s over the last 12 months.

NBY's Price Growth Rating (81) in the Biotechnology industry is in the same range as NCNA (91). This means that NBY’s stock grew similarly to NCNA’s over the last 12 months.

NBY's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NCNA (100). This means that NBY’s stock grew similarly to NCNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBYNCNA
RSI
ODDS (%)
N/A
Bearish Trend 5 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
83%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
82%
MACD
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
89%
Advances
ODDS (%)
Bullish Trend 16 days ago
82%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 16 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
88%
Bearish Trend 5 days ago
85%
Aroon
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Ad is loading...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X83102.830000617.109400
+0.75%
Bitcoin cryptocurrency
SPY536.70-27.82
-4.93%
SPDR® S&P 500® ETF Trust
TSLA267.28-15.48
-5.47%
Tesla
GME21.10-1.59
-7.01%
GameStop Corp
AAPL203.19-20.70
-9.25%
Apple

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
-1.70%
CDTX - NBY
93%
Closely correlated
-2.99%
NCNA - NBY
93%
Closely correlated
-5.57%
WINT - NBY
92%
Closely correlated
-11.51%
SNPX - NBY
91%
Closely correlated
-4.22%
RNAC - NBY
91%
Closely correlated
-4.71%
More

NCNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NCNA has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NCNA
1D Price
Change %
NCNA100%
-5.57%
CDTX - NCNA
93%
Closely correlated
-2.99%
NBY - NCNA
92%
Closely correlated
-1.70%
WINT - NCNA
92%
Closely correlated
-11.51%
RNAC - NCNA
92%
Closely correlated
-4.71%
SNPX - NCNA
92%
Closely correlated
-4.22%
More